PLRX - Pliant Therapeutics: Strange Volatility

2025-02-11 00:31:37 ET

Summary

• Pliant Therapeutics paused its phase 2b/3 trial of bexotegrast for idiopathic pulmonary fibrosis due to DSMB recommendations, causing significant stock volatility.
• High trading volumes and sharp stock declines occurred before the announcement, indicating potential insider activity, making PLRX highly risky for retail investors.
• The DSMB's rationale for pausing the trial remains unclear, with no major safety issues previously reported, adding to the uncertainty.
• PLRX has a cash runway of 5–6 quarters, but faces risks due to volatile stock movements and confusing trial data; I recommend avoiding PLRX.

Note the following timeline:

On Feb. 07, 2025 at 4:58 PM ET, Pliant Therapeutics ( PLRX ) made a major announcement —the company was voluntarily pausing the phase 2b/3 trial of bexotegrast in patients with Idiopathic Pulmonary Fibrosis. You can see the exact time in the press release below....

For further details see: